Skip to content
Evigrade
CriticalClass Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)×Triazole derivatives, systemic antifungals

Updated · Methodology

Mechanism

The liver clears quinidine mainly through the enzyme CYP3A4, and quinidine levels rise, for example, with ketoconazole, probably because of competition for this pathway (quinidine label, US Food and Drug Administration, FDA). Voriconazole strongly inhibits CYP3A4 and can raise the levels of drugs broken down by this enzyme (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). No study has tested the pair. According to the voriconazole SmPC and label, higher quinidine levels can prolong the corrected QT interval (QTc) and, rarely, cause torsade de pointes (voriconazole SmPC, EMA, and label, FDA). Quinidine itself prolongs the QT interval in a dose-related way. The risk of torsade de pointes is higher with high quinidine blood levels, a slow heart rate and low potassium, magnesium or calcium (quinidine FDA label). QTc prolongation has also occurred with voriconazole (voriconazole SmPC, EMA).

Symptoms

Prolongation of the corrected QT interval (QTc) itself causes no symptoms and shows only on the electrocardiogram (ECG). Ventricular arrhythmias cause palpitations, dizziness or fainting. Life-threatening torsade de pointes, frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation have been reported with quinidine (quinidine label, US Food and Drug Administration, FDA). Too much quinidine also causes low blood pressure, vomiting, diarrhoea, tinnitus, high-frequency hearing loss, vertigo, blurred and double vision, sensitivity to light, headache, confusion and delirium (quinidine FDA label). Rare cases of torsade de pointes, cardiac arrest and sudden death have occurred with voriconazole itself, usually in seriously ill patients with other risk factors (voriconazole FDA label).

Management

The combination is contraindicated. The voriconazole summaries of product characteristics (SmPCs) name quinidine among the drugs that must not be given with voriconazole. These drugs depend heavily on the enzyme CYP3A4 for their metabolism, and high levels of them are linked to serious or life-threatening reactions (voriconazole SmPCs, European Medicines Agency, EMA, and Spanish Agency of Medicines and Medical Devices, AEMPS). The US voriconazole label also contraindicates quinidine, because its levels are likely to rise, with a risk of QT prolongation and rare torsade de pointes (voriconazole label, US Food and Drug Administration, FDA). The quinidine label does not mention voriconazole. According to it, drugs that change quinidine levels can cause toxicity or loss of effect unless the quinidine dose is adjusted (quinidine FDA label). Check potassium, magnesium and calcium before and during voriconazole treatment and correct them if needed (voriconazole SmPC, EMA, and label, FDA). The corrected QT interval (QTc) on the electrocardiogram (ECG) predicts quinidine-induced ventricular arrhythmias better than the quinidine blood level (quinidine FDA label). If the patient has nevertheless taken both drugs and develops haemodynamically unstable polymorphic ventricular tachycardia, including torsade de pointes, stop quinidine. Perform immediate cardioversion or, if a pacemaker is in place or immediately available, immediate overdrive pacing. Look for low potassium, magnesium and calcium and correct them actively (quinidine FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Quinidine

Other interactions with Voriconazole